Arcutis Biotherapeutics, Inc. announced new individual patient response data showing the vast majority of individuals treated with investigational roflumilast cream 0.15% had a measurable improvement in Eczema Area and Severity Index in 4 weeks.
Arcutis Biotherapeutics, Inc. announced new individual patient response data showing the vast majority of individuals treated with investigational roflumilast cream 0.15% had a measurable improvement in Eczema Area and Severity Index in 4 weeks.